Exactech, Inc. (EXAC) Misses Q2 EPS by 1c; Updates FY12 Outlook; Guides Q3
Tweet
Share
E-mailGet Alerts EXAC Hot Sheet
Price: $49.25 --0%
Financial Fact:
Sales and marketing: 21.68M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Sales and marketing: 21.68M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Exactech, Inc. (NASDAQ: EXAC) reported Q2 EPS of $0.23, $0.01 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $55.2 million versus the consensus estimate of $56.09 million.
Exactech, Inc. sees FY2012 EPS of $0.91-$0.95, versus the consensus of $0.94. Exactech, Inc. sees FY2012 revenue of $218-$223 million, versus the consensus of $222.9 million.
Exactech, Inc. sees Q3 2012 EPS of $0.17-$0.19, versus the consensus of $0.18. Exactech, Inc. sees Q3 2012 revenue of $49-$51 million, versus the consensus of $51.02 million.
For earnings history and earnings-related data on Exactech, Inc. (EXAC) click here.
Exactech, Inc. sees FY2012 EPS of $0.91-$0.95, versus the consensus of $0.94. Exactech, Inc. sees FY2012 revenue of $218-$223 million, versus the consensus of $222.9 million.
Exactech, Inc. sees Q3 2012 EPS of $0.17-$0.19, versus the consensus of $0.18. Exactech, Inc. sees Q3 2012 revenue of $49-$51 million, versus the consensus of $51.02 million.
For earnings history and earnings-related data on Exactech, Inc. (EXAC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
- Vivos Therapeutics posts 35% revenue gain but widens net loss
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
